Aim To evaluate the effect in patients with obese T2DM treated with liraglutide, through measuring epicardial adipose tissue(EAT) thickness with echocardiography. Methods 36 patients with obese T2DM were included and treated with liraglutide monotheraphy. EAT thickness was measured with echocardiography, before treatment and after 3-month treatment, meanwhile anthropometric indictors and biochemical indictors(fasting blood-glucose, HbA1c, et al) were detected. The correlation between variation of EAT thickness and variation of anthropometric indicators was analyzed. Results EAT thickness was reduced significantly after treatment(P<0.05). Especially, the variation of EAT thickness had significantly positive correlation with the variation of waist circumference(WC), hip circumference(HC) and body mass index(BMI). Conclusions EAT as measured with echocardiography can assess the efficacy of liraglutide in patients with obese T2DM .